サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405755

先進治療医薬品の市場規模、シェア、動向分析レポート：治療製品タイプ別、地域別、セグメント別予測、2023年～2030年

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), By Region (North America, Europe, APAC, ROW), And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
先進治療医薬品の市場規模、シェア、動向分析レポート：治療製品タイプ別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年12月01日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

先進治療医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の先進治療医薬品市場規模は2030年までに909億8,000万米ドルに達し、予測期間中に16.8%のCAGRを記録すると予測されています。

ATMP（Advanced Therapy Medicinal Products）は、対症療法ではなく根本的な原因に対処することで病気を治す可能性を示します。そのため、ATMPは従来の治療法では得られなかった革新的な利点を提供するのに役立ちます。このような要因が、予測期間中、市場を牽引すると予想されます。

Zolgensma、Kymriah、Yescartaの承認後のTecartusとAbecmaの画期的な承認は、この分野における卓越した進歩を後押ししています。これらの承認は、この分野への投資の流れに拍車をかけ、収益の成長を促しています。主要企業は、製品製造プロセスを加速させるために様々なオペレーションモデルを採用しています。

さらに、この分野への参入や既存事業の拡大を意図した企業による買収もいくつか見られました。Gilead Life Science社によるKite Pharma社の買収、Novartis社によるAveXis社の買収、Celgene社によるJuno Therapeutics社の買収などが、最近の主な例です。これらの買収は、この市場における老舗製薬会社の関心の高まりを物語っています。遺伝子治療の買収競争は激化しており、高額なプレミアムが発生する可能性があります。

一方、消費者の需要が高まるにつれ、ATMPメーカーは製品製造を外注するようになり、製造受託機関に有利な機会が生まれています。そのため、複数のCDMOが施設を拡張しています。例えば、2021年1月、FUJIFILM Diosynth Biotechnologiesは先端療法とウイルスベクターの新しいプロセス開発と製造施設の設立のために4,000万米ドルを投資しました。

先進治療医薬品市場のレポートハイライト

  • 日本と欧州におけるYescartaとKymriahの地理的拡大は、投資家によるこの分野での開発支援を後押ししています。
  • 最近の遺伝子治療の承認により、この分野の臨床試験が大幅に加速しています。
  • COVID-19パンデミックは、主要企業がウイルス感染症に対するT細胞研究に投資する新たな分野を開拓しました。
  • 研究界はCOVID-19患者における先進的治療の可能性を積極的に評価しており、市場成長の一助となっています。
  • 北米は、先進治療に関する臨床試験の急激な増加により、2022年に最大の売上シェアを占めました。
  • 米国ではATMPの強力なパイプラインが同地域の収益創出を加速しました。
  • また、米国を拠点とする企業が従来の医薬品開発からATMPSに重点を移していることも、同地域の成長を後押ししています。
  • アジア太平洋地域では、中国を筆頭とする新興市場におけるATMP市場の拡大により、市場のCAGRが最も速くなると予想されます。
  • 中国を拠点とするCDMOの事業拡大が地域市場の成長を牽引しています。
  • 主要企業は市場での地位を維持するために様々な戦略的取り組みを行っています。2021年1月のViGeneron GmbHとBiogen Inc.の提携は、この分野における提携の顕著な例の一つです。
  • 両社は遺伝性眼疾患治療のためのAAVベースの遺伝子治療製品の開発で協力しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 先進治療医薬品市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 高度な治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 先進治療医薬品：タイプの推定・動向分析

  • 先進治療医薬品市場：重要なポイント
  • 先進治療医薬品市場：動向と市場シェア分析、2022年および2030年
  • 細胞治療
  • 遺伝子治療
  • 組織工学的加工製品

第5章 先進治療医薬品市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別の先進治療医薬品市場：主要マーケットプレースの要点
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Spark Therapeutics, Inc.
    • Bluebird Bio, Inc
    • Novartis AG
    • UniQure N.V.
    • Celgene Corporation
    • Gilead Lifesciences, Inc
    • Kolon TissueGene, Inc
    • JCR Pharmaceuticals Co., Ltd.
    • MEDIPOST
    • Vericel Corporation
    • PHARMICELL Co., Ltd
    • Organogenesis Inc.
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 3 North America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 5 Canada advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 6 Europe advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 7 Europe advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 9 UK advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 10 France advanced therapy medicinal products, by therapy type, 2018 - 2030 (USD Million)
  • Table 11 Italy advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 12 Spain advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 13 Sweden advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 14 Norway advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 15 Denmark advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 18 China advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 19 Japan advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 20 India advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 21 Thailand advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 22 South Korea advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 23 Latin America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 24 Latin America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 25 Brazil advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 26 Mexico advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 27 Argentina advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 28 Middle East and Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
  • Table 30 South Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 31 Saudi Arabia advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 32 UAE advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
  • Table 33 Kuwait advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Advanced therapy medicinal products: market outlook
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 Advanced therapy medicinal products market driver impact
  • Fig. 14 Advanced therapy medicinal products market restraint impact
  • Fig. 15 Advanced therapy medicinal products market strategic initiatives analysis
  • Fig. 16 Advanced therapy medicinal products market: type movement analysis
  • Fig. 17 Advanced therapy medicinal products market: type outlook and key takeaways
  • Fig. 18 Cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Tissue engineered product market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Global Advanced therapy medicinal products market: regional movement analysis
  • Fig. 22 Global Advanced therapy medicinal products market: regional outlook and key takeaways
  • Fig. 23 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-855-8

Advanced Therapy Medicinal Products Market Growth & Trends:

The global advanced therapy medicinal products market size is expected to reach USD 90.98 billion by 2030, registering a CAGR of 16.8% during the forecast period, according to a new report by Grand View Research, Inc. The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

Advanced Therapy Medicinal Products Market Report Highlights:

  • The geographical expansion of Yescarta and Kymriah in Japan and Europe has encouraged the investors to support the development in this space
  • Recent approvals of gene therapies have significantly accelerated the clinical trials in this segment
  • COVID-19 pandemic has opened new areas for key players to invest in T-cell research for viral infections
  • The research community is actively evaluating the potential of advanced therapies in COVID-19 patients, thereby aiding in market growth
  • North America accounted for the largest revenue share in 2022 owing to the exponential rise in clinical trials pertaining to advanced therapies
  • Strong pipeline of ATMPs in the U.S. accelerated revenue generation in the region
  • Also, the shifting focus of U.S.-based companies from conventional drug development to ATMPS is driving regional growth
  • In Asia Pacific, the market is expected to witness the fastest CAGR owing to expanding ATMP landscape in emerging markets such as China at the forefront
  • Expanding business of China-based CDMOs has driven regional market growth
  • Key companies are undertaking various strategic initiatives to maintain their market position. Collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space
  • The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapy Type
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Advanced Therapy Medicinal Products Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Advanced Therapy Medicinal Products Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Advanced Therapy Medicinal Products: Type Estimates & Trend Analysis

  • 4.1. Advanced Therapy Medicinal Products Market: Key Takeaways
  • 4.2. Advanced Therapy Medicinal Products Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Cell Therapy
    • 4.3.1. Cell therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Gene therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Tissue Engineered Product
    • 4.5.1. Tissue engineered product market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Product Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Advanced Therapy Medicinal Products Market by Region: Key Marketplace Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Spark Therapeutics, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bluebird Bio, Inc
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Novartis AG
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. UniQure N.V.
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Celgene Corporation
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Gilead Lifesciences, Inc
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Kolon TissueGene, Inc
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. JCR Pharmaceuticals Co., Ltd.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. MEDIPOST
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Vericel Corporation
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. PHARMICELL Co., Ltd
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
    • 6.2.12. Organogenesis Inc.
      • 6.2.12.1. Company overview
      • 6.2.12.2. Financial performance
      • 6.2.12.3. Product benchmarking
      • 6.2.12.4. Strategic initiatives